Breast Cancer Therapy
Reports from Mayo Clinic, Division of Medical Oncology add new data to research in breast cancer therapy
Published in Drug Law Weekly, February 6th, 2007
New research, "Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial," is the subject of a report. According to recent research published in the journal Breast Cancer Research and Treatment, "MA.17 was a double-blind placebo-controlled trial involving 5187 postmenopausal women that established letrozole to be of value in reducing recurrence of breast cancer when given in the extended adjuvant therapy setting after about 5 years of tamoxifen. Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes."
"The final MA.17 database that included all events up...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-02-06)
More Articles from Drug Law Weekly
- Business Update
Express Scripts describes offer for Caremark as superior - Business Update
Express Scripts nominates four directors for Caremark board of directors - Healthcare Policy
Foundation suggests Schwarzenegger health plan's success depends on affordability - Hip Fractures
Study suggests hip fractures are not caused by benzodiazepine use after all - Legal Issues
MedImmune reports court denied Sun Pharmaceutical's motion to end generic amifostine action - Legal Issues
Ninth doctor sentenced in illegal Internet prescription drug distributions - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
